Literature DB >> 27312032

Hepatocellular carcinoma: From diagnosis to treatment.

Miral Sadaria Grandhi1, Amy K Kim2, Sean M Ronnekleiv-Kelly1, Ihab R Kamel3, Mounes A Ghasebeh3, Timothy M Pawlik4.   

Abstract

Primary liver cancer is the sixth most common cancer overall and the second most common cause of cancer mortality worldwide. Hepatocellular carcinoma accounts for up to 90% of all primary hepatic malignancies and represents a major international health problem. While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional therapy and sorafenib are beneficial in those with more advanced disease or those who are not surgical candidates. At times, the integration of both surgical and locoregional therapy may be necessary. Hence, hepatocellular carcinoma requires a multidisciplinary approach to determine the most appropriate treatment as well as the timing of various treatments for optimal outcomes.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ablation; Functional MRI; Hepatocellular carcinoma; Liver transplantation; Sorafenib; Transarterial chemoembolization (TACE)

Mesh:

Year:  2016        PMID: 27312032     DOI: 10.1016/j.suronc.2016.03.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  145 in total

1.  Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.

Authors:  Ting Ni; Xiao-Sha Shang; Wen-Tao Wang; Xin-Xing Hu; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

2.  Construction of ceRNA network and identification of two differentially expressed circRNAs in hepatocellular carcinoma by bioinformatic analysis.

Authors:  Hongwei He; Zhong Shen; Qiyun Gu; Rong Xie
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

Review 3.  Liver Allocation Policies in the USA: Past, Present, and the Future.

Authors:  Anjana Pillai; Thomas Couri; Michael Charlton
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

4.  A Multidisciplinary Team Approach to the Management of Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Authors:  Shuqun Cheng; Xubiao Wei; Jie Shi; Weixing Guo; Shuang Feng; Jian Zhai; Bin Huang
Journal:  Oncologist       Date:  2020-03-06

5.  Improving the heating efficiency of high intensity focused ultrasound ablation through the use of phase change nanodroplets and multifocus sonication.

Authors:  Aparna Singh; A Gloria Nyankima; M Anthony Phipps; Vandiver Chaplin; Paul A Dayton; Charles Caskey
Journal:  Phys Med Biol       Date:  2020-10-12       Impact factor: 3.609

6.  A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.

Authors:  Qiaohua Zhu; Meihua Luo; Chengyu Zhou; Zhiwei Zhou; Zhixu He; Xinfa Yu; Shufeng Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead.

Authors:  Lihui Weng; Hsiang-Jer Tseng; Parinaz Rostamzadeh; Jafar Golzarian
Journal:  J Mater Sci Mater Med       Date:  2016-10-17       Impact factor: 3.896

8.  Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Authors:  James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

9.  Anomalous branching pattern of the portal vein: right posterior portal vein originating from the left portal vein.

Authors:  Koichiro Yasaka; Hiroyuki Akai; Shigeru Kiryu
Journal:  Surg Radiol Anat       Date:  2016-10-03       Impact factor: 1.246

10.  LncRNA FLJ33360 accelerates the metastasis in hepatocellular carcinoma by targeting miRNA-140/MMP9 axis.

Authors:  Zhenhui Lu; Yingzi Yu; Xiangchun Ding; Dong Jin; Genwang Wang; Yu Zhou; Yongzhao Zhu; Li Na; Yaqin He; Qi Wang
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.